Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$14.16 USD
+0.44 (3.21%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $14.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TAK 14.16 +0.44(3.21%)
Will TAK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Other News for TAK
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
TAK Crosses Below Key Moving Average Level
Takeda (TAK) Reaffirms FY25 Financial Projections
Takeda (TAK) Reports Decline in Q1 Revenue Amid Potential Pipeline Growth
Takeda reports Q1 core EPS 151 yen vs. 176 yen last year